rs121913377
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
These data suggest additive, combinatorial activity between radiation and PLX4720 in cancers carrying BRAF V600E mutations.
|
23354848 |
2013 |
rs121913377
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
We previously repositioned the drug as the inhibitor of B-Raf V600E, but its anti-tumor effect in human cancer has never been reported.
|
30583070 |
2019 |
rs121913377
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
The purpose of this study was to evaluate the feasibility of core-needle biopsy with BRAF(V600E) mutation analysis (CNB + BRAF(V600E) ) and to compare the clinical usefulness of CNB + BRAF(V600E) and fine-needle aspiration with BRAF(V600E) mutation analysis (FNA + BRAF(V600E) ) in the diagnosis of thyroid malignancy.
|
26215382 |
2016 |
rs121913377
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
For the 37 cases cytologists favored to be cPTC, 31 (84%) had a molecular result that supported malignancy (28 BRAF V600E mutations, 2 NTRK1 fusions, 1 AGK-BRAF fusion).
|
29396809 |
2018 |
rs121913377
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF-V600E mutations are found in a broad spectrum of cancer types and can be successfully targeted by specific therapeutic compounds.
|
23343956 |
2013 |
rs121913377
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
We hypothesized it would be more commonly methylated and inactivated in serrated pathway colorectal cancers that are hallmarked by a BRAF V600E mutation and a methylator phenotype, compared to traditional pathway cancers that are BRAF wild type.
|
25613750 |
2015 |
rs121913377
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
The BRAF(V600E) mutation is common in several human cancers, especially melanoma.
|
20551065 |
2010 |
rs121913377
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Detection of the BRAF V600E mutation is therefore a useful adjunct in the differential diagnosis of HCL and HCL variant and highlights the value of a multifaceted approach to the diagnosis of this malignancy.
|
22313586 |
2012 |
rs121913377
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
We performed a literature review of five commonly requested off-label IHC predictive biomarkers in gastrointestinal tract (GIT) malignancies: HER2, mismatch repair (MMR), PD-L1, BRAF V600E and ROS1.
|
31221175 |
2019 |
rs121913377
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
This combinatorial effect was recapitulated in human melanoma-derived cell lines and was restricted to cancers bearing a BRAF(V600E) mutation.
|
25358764 |
2015 |
rs121913377
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
The BRAF inhibitor vemurafenib has become an important treatment option for melanoma patients, the majority of whom have a BRAF(V600E) mutation driving their malignancy.
|
23074264 |
2012 |
rs121913377
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Two patients with treatment-refractory high-grade colorectal neuroendocrine tumors harboring BRAF(V600E) exhibited rapid and durable response to combined BRAF-MEK inhibition, providing the first clinical evidence of efficacy in this aggressive tumor type.Cancer Discov; 6(6); 594-600.
|
27048246 |
2016 |
rs121913377
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
These data demonstrate that clonal BRAF(V600E) is a rare occurrence in PTC, although frequently this cancer consists of a mixture of tumor cells with wild-type and mutant BRAF.
|
22170714 |
2012 |
rs121913377
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
None of the 504 benign, 45 (31.9%) of the 141 ACUS, 46 (85.2%) of the 54 suspicious for malignancy, 129 (92.1%) of the 140 malignant, and one (10%) of the 10 suspicious for follicular neoplasm cases showed BRAF(V600E) mutation.
|
21239517 |
2011 |
rs121913377
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Verteporfin is highly effective as concentrations of verteporfin that do not impact tumor formation restore BRAF inhibitor suppression of tumor formation, suggesting that co-treatment with agents that inhibit YAP1 and BRAF(V600E) may be a viable therapy for cancer stem cell-derived BRAF inhibitor-resistant melanoma.
|
29299145 |
2017 |
rs121913377
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
The BRAF(V600E) mutation was identified in 13 patients (4%), 12 of whom had either cytologic atypia or were Bethesda category V. Three percent of Bethesda category III or IV nodules that were malignant harbored the mutation compared with 42% of Bethesda category V malignancies.
|
23280049 |
2013 |
rs121913377
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Besides confirming the constant presence of BRAF-V600E in all patients with hairy cell leukemia, we observed ubiquitous phospho-ERK expression in this malignancy.
|
23349307 |
2013 |
rs121913377
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
This study demonstrates the activating BRAF mutation (V600E), which is found in multiple human cancers, is a driver of canine InvTCC, and highlights a urine-based test for quick diagnosis.
|
25767210 |
2015 |
rs121913377
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Our findings provide evidence of critical survival signals in BRAF non-V600E mutant c</span>ancers, which could pave the way for effective treatment of these cancers.
|
29348459 |
2018 |
rs121913377
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Cytomorphologic features can help select nodules for the BRAF(V600E) mutation test among nodules read as "suspicious for malignancy" on cytology.
|
26187369 |
2015 |
rs121913377
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Although the presence of the BRAF V600E mutation is indicative of a sporadic cancer, up to 30% to 50% of colorectal carcinomas with MLH1 promoter hypermethylation will lack a BRAF mutation.
|
27438990 |
2016 |
rs121913377
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
The presence of the noninheritable V600E BRAF mutation in this family supports Knudson's "double-hit" hypothesis for cancer development and suggests the involvement of more than 1 gene in the clinical expression of FNMTC.
|
29895015 |
2018 |
rs121913377
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Notch functions as an oncogene or tumor suppressor according to the type of malignancy, and the BRAF(V600E) mutation is commonly observed in thyroid cancer.
|
22118425 |
2012 |
rs121913377
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
PGC1α-negative papillary cancer was associated with BRAF V600E mutation, large tumor size, extrathyroidal or lymphovascular invasion, lymph node metastasis, and advanced stage.
|
31333799 |
2019 |
rs121913377
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Efficacy and tolerability of vemurafenib in patients with BRAF(V600E) -positive papillary thyroid cancer: M.D. Anderson Cancer Center off label experience.
|
25353071 |
2015 |